vs
Apellis Pharmaceuticals, Inc.（APLS）与Ingevity Corp（NGVT）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Ingevity Corp的1.1倍（$199.9M vs $185.4M），Apellis Pharmaceuticals, Inc.净利率更高（-29.5% vs -45.6%，领先16.1%），Ingevity Corp同比增速更快（36.7% vs -5.9%），Ingevity Corp自由现金流更多（$73.5M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -26.2%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Ingevity Corp是一家全球特种化学品与先进材料生产商，主营高性能碳材料、路面养护解决方案及特种化工产品，服务汽车排放控制、工业净化、道路基建、农业投入品等核心市场，业务覆盖北美、欧洲及亚太地区。
APLS vs NGVT — 直观对比
营收规模更大
APLS
是对方的1.1倍
$185.4M
营收增速更快
NGVT
高出42.7%
-5.9%
净利率更高
APLS
高出16.1%
-45.6%
自由现金流更多
NGVT
多$87.8M
$-14.3M
两年增速更快
APLS
近两年复合增速
-26.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $185.4M |
| 净利润 | $-59.0M | $-84.6M |
| 毛利率 | — | 41.2% |
| 营业利润率 | -25.6% | -47.7% |
| 净利率 | -29.5% | -45.6% |
| 营收同比 | -5.9% | 36.7% |
| 净利润同比 | -62.2% | -609.6% |
| 每股收益（稀释后） | $-0.40 | $-2.33 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSNGVT
| Q4 25 | $199.9M | $185.4M | ||
| Q3 25 | $458.6M | $333.1M | ||
| Q2 25 | $178.5M | $365.1M | ||
| Q1 25 | $166.8M | $284.0M | ||
| Q4 24 | $212.5M | $135.6M | ||
| Q3 24 | $196.8M | $333.8M | ||
| Q2 24 | $199.7M | $390.6M | ||
| Q1 24 | $172.3M | $340.1M |
净利润APLSNGVT
| Q4 25 | $-59.0M | $-84.6M | ||
| Q3 25 | $215.7M | $43.5M | ||
| Q2 25 | $-42.2M | $-146.5M | ||
| Q1 25 | $-92.2M | $20.5M | ||
| Q4 24 | $-36.4M | $16.6M | ||
| Q3 24 | $-57.4M | $-107.2M | ||
| Q2 24 | $-37.7M | $-283.7M | ||
| Q1 24 | $-66.4M | $-56.0M |
毛利率APLSNGVT
| Q4 25 | — | 41.2% | ||
| Q3 25 | — | 40.2% | ||
| Q2 25 | — | 37.8% | ||
| Q1 25 | — | 39.9% | ||
| Q4 24 | — | 81.3% | ||
| Q3 24 | — | 39.4% | ||
| Q2 24 | — | 31.5% | ||
| Q1 24 | — | 29.3% |
营业利润率APLSNGVT
| Q4 25 | -25.6% | -47.7% | ||
| Q3 25 | 48.7% | 18.7% | ||
| Q2 25 | -18.6% | -39.1% | ||
| Q1 25 | -50.0% | 9.4% | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -24.0% | 33.0% | ||
| Q2 24 | -14.7% | 25.9% | ||
| Q1 24 | -36.0% | 22.6% |
净利率APLSNGVT
| Q4 25 | -29.5% | -45.6% | ||
| Q3 25 | 47.0% | 13.1% | ||
| Q2 25 | -23.6% | -40.1% | ||
| Q1 25 | -55.3% | 7.2% | ||
| Q4 24 | -17.1% | 12.2% | ||
| Q3 24 | -29.2% | -32.1% | ||
| Q2 24 | -18.9% | -72.6% | ||
| Q1 24 | -38.5% | -16.5% |
每股收益（稀释后）APLSNGVT
| Q4 25 | $-0.40 | $-2.33 | ||
| Q3 25 | $1.67 | $1.18 | ||
| Q2 25 | $-0.33 | $-4.02 | ||
| Q1 25 | $-0.74 | $0.56 | ||
| Q4 24 | $-0.30 | $0.44 | ||
| Q3 24 | $-0.46 | $-2.94 | ||
| Q2 24 | $-0.30 | $-7.81 | ||
| Q1 24 | $-0.54 | $-1.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $78.1M |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $370.1M | $29.7M |
| 总资产 | $1.1B | $1.7B |
| 负债/权益比越低杠杆越低 | — | 39.10× |
8季度趋势，按日历期对齐
现金及短期投资APLSNGVT
| Q4 25 | $466.2M | $78.1M | ||
| Q3 25 | $479.2M | $83.4M | ||
| Q2 25 | $370.0M | $76.9M | ||
| Q1 25 | $358.4M | $71.5M | ||
| Q4 24 | $411.3M | $68.0M | ||
| Q3 24 | $396.9M | $135.5M | ||
| Q2 24 | $360.1M | $107.4M | ||
| Q1 24 | $325.9M | $88.5M |
总债务APLSNGVT
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | $93.1M | $1.4B |
股东权益APLSNGVT
| Q4 25 | $370.1M | $29.7M | ||
| Q3 25 | $401.2M | $138.1M | ||
| Q2 25 | $156.3M | $120.7M | ||
| Q1 25 | $164.2M | $234.6M | ||
| Q4 24 | $228.5M | $195.2M | ||
| Q3 24 | $237.1M | $214.5M | ||
| Q2 24 | $264.3M | $284.8M | ||
| Q1 24 | $266.7M | $568.2M |
总资产APLSNGVT
| Q4 25 | $1.1B | $1.7B | ||
| Q3 25 | $1.1B | $1.8B | ||
| Q2 25 | $821.4M | $1.9B | ||
| Q1 25 | $807.3M | $2.1B | ||
| Q4 24 | $885.1M | $2.0B | ||
| Q3 24 | $901.9M | $2.2B | ||
| Q2 24 | $904.5M | $2.3B | ||
| Q1 24 | $831.9M | $2.6B |
负债/权益比APLSNGVT
| Q4 25 | — | 39.10× | ||
| Q3 25 | — | 8.39× | ||
| Q2 25 | — | 10.24× | ||
| Q1 25 | — | 5.68× | ||
| Q4 24 | — | 6.86× | ||
| Q3 24 | — | 6.52× | ||
| Q2 24 | — | 4.92× | ||
| Q1 24 | 0.35× | 2.48× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $97.1M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $73.5M |
| 自由现金流率自由现金流/营收 | -7.1% | 39.6% |
| 资本支出强度资本支出/营收 | 0.1% | 12.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $273.5M |
8季度趋势，按日历期对齐
经营现金流APLSNGVT
| Q4 25 | $-14.2M | $97.1M | ||
| Q3 25 | $108.5M | $129.7M | ||
| Q2 25 | $4.4M | $79.0M | ||
| Q1 25 | $-53.4M | $25.4M | ||
| Q4 24 | $19.4M | $64.5M | ||
| Q3 24 | $34.1M | $46.5M | ||
| Q2 24 | $-8.3M | $29.7M | ||
| Q1 24 | $-133.0M | $-12.1M |
自由现金流APLSNGVT
| Q4 25 | $-14.3M | $73.5M | ||
| Q3 25 | $108.3M | $117.8M | ||
| Q2 25 | $4.4M | $66.8M | ||
| Q1 25 | $-53.4M | $15.4M | ||
| Q4 24 | $19.3M | $39.6M | ||
| Q3 24 | — | $28.5M | ||
| Q2 24 | $-8.4M | $11.6M | ||
| Q1 24 | $-133.3M | $-28.7M |
自由现金流率APLSNGVT
| Q4 25 | -7.1% | 39.6% | ||
| Q3 25 | 23.6% | 35.4% | ||
| Q2 25 | 2.5% | 18.3% | ||
| Q1 25 | -32.0% | 5.4% | ||
| Q4 24 | 9.1% | 29.2% | ||
| Q3 24 | — | 8.5% | ||
| Q2 24 | -4.2% | 3.0% | ||
| Q1 24 | -77.3% | -8.4% |
资本支出强度APLSNGVT
| Q4 25 | 0.1% | 12.7% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | 0.0% | 3.3% | ||
| Q1 25 | 0.0% | 3.5% | ||
| Q4 24 | 0.0% | 18.4% | ||
| Q3 24 | 0.0% | 5.4% | ||
| Q2 24 | 0.0% | 4.6% | ||
| Q1 24 | 0.2% | 4.9% |
现金转化率APLSNGVT
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 2.98× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.24× | ||
| Q4 24 | — | 3.89× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
NGVT
| Performance Materials | $151.2M | 82% |
| Advanced Polymer Technologies Segment | $36.5M | 20% |
